Sacubitril And Valsartan Tablet, Film Coated
NDC Package 67877-708-51
Package Information
Sacubitril And Valsartan tablets is sacubitril and valsartan is contraindicated: • in patients with hypersensitivity to any component • in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy [see Warnings and Precautions (5.2)] • with concomitant use of ACE inhibitors. This formulation utilizes a tablet, film coated delivery system. Marketed by Ascend Laboratories, Llc, this product is identified by NDC 67877-708 and is authorized under FDA application ANDA213764.
Identification & Billing
- RxCUI: 1656340 - sacubitril 24 MG / valsartan 26 MG Oral Tablet
- RxCUI: 1656349 - sacubitril 49 MG / valsartan 51 MG Oral Tablet
- RxCUI: 1656354 - sacubitril 97 MG / valsartan 103 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 67877 - Ascend Laboratories, Llc
- 67877-708 - Sacubitril And Valsartan
- 67877-708-51 - 180 TABLET, FILM COATED in 1 BOTTLE
- 67877-708 - Sacubitril And Valsartan
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (67877-708). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 67877-708-51 identifies a specific commercial package of 180 tablet, film coated in 1 bottle of Sacubitril And Valsartan, a human prescription drug labeled by Ascend Laboratories, Llc. This tablet, film coated is formulated for oral use and contains sacubitril; valsartan as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Ascend Laboratories, Llc on July 23, 2025. The current certification is valid through December 31, 2026.
How is this Ascend Laboratories, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 67877070851. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.